DUBLIN–(BUSINESS WIRE)–The “Sysmex Corp (6869) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering. ThisDUBLIN–(BUSINESS WIRE)–The “Sysmex Corp (6869) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering. This

Sysmex Corp (6869) Product Pipeline Analysis Report 2025: Haematology, Haemostasis, and Urinalysis Analyzers – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Sysmex Corp (6869) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

Sysmex Corp (Sysmex) is a provider of medical devices that researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. It offers diagnostic instruments, reagents and laboratory information systems to clinical laboratories for testing.

The company’s offerings include haematology, haemostasis, and urinalysis analyzers. Its products are used by medical institutions. It conducts research and development at its facilities in Japan, France, New Zealand, Germany and the US. The company operates along with its subsidiaries in the Americas, Europe, the Middle East, Africa and Asia Pacific. Sysmex is headquartered in Hyogo, Japan.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Report Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Sysmex Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Sysmex Corp, Recent Developments

  • Dec 15, 2025: A compact model has been added to the CN series
  • Dec 11, 2025: Sysmex Introduces Compact Model to CN-Series
  • Nov 24, 2025: Revolutionising UTIs Diagnosis and Treatment in 45 Minutes
  • Nov 04, 2025: Sysmex Introduces Two Testing Parameters for Hypertension Immunoassay Panel in Japan
  • Oct 10, 2025: Cytocell Received CLIA Approval for CytoCell KMT2A Breakapart FISH Probe Kit PDx
  • Oct 01, 2025: Sysmex Partners with QIAGEN for Exclusive Distribution and Supply of Clinical Diagnostic Products in Infectious Diseases and Oncology in Japan
  • Oct 01, 2025: Sysmex and QIAGEN Enter Strategic Alliance for Clinical Diagnostic Product Distribution in Japan
  • Sep 30, 2025: Cytocell Receives DeNovo Clearance for CytoCell KMT2A Breakapart FISH Probe Kit PDx
  • Sep 25, 2025: CytoCell KMT2A Breakapart FISH Probe Kit PDx Receives U.S. FDA Premarket Authorization (De Novo) – Contributing to Expanded Treatment Opportunities for Patients with Acute Leukemia – (OGT)
  • Sep 22, 2025: OGT Companion Diagnostic Receives FDA Approval for Identifying Acute Leukaemia Patients with KMT2Ar

Key Topics Covered:

  • Sysmex Corp Company Overview
  • Sysmex Corp Company Snapshot
  • Sysmex Corp Pipeline Products and Ongoing Clinical Trials Overview
  • Sysmex Corp – Pipeline Analysis Overview
  • Business Description
  • Sysmex Corp – Key Facts
  • Sysmex Corp – Major Products and Services
  • Sysmex Corp Pipeline Products by Development Stage
  • Sysmex Corp Pipeline Products Overview
  • Antigen Saliva Test – COVID-19
  • Antigen Saliva Test – COVID-19 Product Overview
  • Antigen Test – COVID-19
  • Antigen Test – COVID-19 Product Overview
  • Blood-based Diagnostic Assay – Cancer
  • Blood-based Diagnostic Assay – Cancer Product Overview
  • Cancer Diagnostic Reagent
  • Cancer Diagnostic Reagent Product Overview
  • Cancer Related Gene Panel Test System
  • Cancer Related Gene Panel Test System Product Overview
  • Captiver System
  • Captiver System Product Overview
  • Companion Diagnostic DNA Test
  • Companion Diagnostic DNA Test Product Overview
  • Diagnostic Assay – Colorectal Cancer
  • Diagnostic Assay – Colorectal Cancer Product Overview
  • Diagnostic Test – Atopic Dermatitis
  • Diagnostic Test – Atopic Dermatitis Product Overview
  • Diagnostic Test – Liver Fibrosis
  • Diagnostic Test – Liver Fibrosis Product Overview
  • Diagnostic Test – Pancreatic Cancer
  • Diagnostic Test – Pancreatic Cancer Product Overview
  • Fully Automatic Blood and Body Fluid Analyzer XR-10[B1]
  • Fully Automatic Blood and Body Fluid Analyzer XR-10[B1] Product Overview
  • Fully Automatic Blood and Body Fluid Analyzer XR-10[B2]
  • Fully Automatic Blood and Body Fluid Analyzer XR-10[B2] Product Overview
  • Fully Automatic Blood and Body Fluid Analyzer XR-10[B3]
  • Fully Automatic Blood and Body Fluid Analyzer XR-10[B3] Product Overview
  • HISCL Blood Based Test – Alzheimer’s Disease
  • HISCL Blood Based Test – Alzheimer’s Disease Product Overview
  • HISCL CSF Based Test – Alzheimer’s Disease
  • HISCL CSF Based Test – Alzheimer’s Disease Product Overview
  • Immuno-flowFISH – Bone Marrow Cancer
  • Immuno-flowFISH – Bone Marrow Cancer Product Overview
  • Immuno-flowFISH Test – Leukaemia
  • Immuno-flowFISH Test – Leukaemia Product Overview
  • Immunochemistry Test – Bile Duct Cancer
  • Immunochemistry Test – Bile Duct Cancer Product Overview
  • Immunochemistry Test – CK19F
  • Immunochemistry Test – CK19F Product Overview
  • Immunochemistry Test – HAV Ab
  • Immunochemistry Test – HAV Ab Product Overview
  • Immunochemistry Test – HBc IgM
  • Immunochemistry Test – HBc IgM Product Overview
  • Immunochemistry Test – Tg Ab
  • Immunochemistry Test – Tg Ab Product Overview
  • Immunochemistry Test – TPO Ab
  • Immunochemistry Test – TPO Ab Product Overview
  • Immunochemistry Test – TR Ab
  • Immunochemistry Test – TR Ab Product Overview
  • Liquid Biopsy System
  • Liquid Biopsy System Product Overview
  • Minimally Invasive Postprandial Hyperglycemia Monitoring System
  • Minimally Invasive Postprandial Hyperglycemia Monitoring System Product Overview
  • Multiplex Gene Panel Test
  • Multiplex Gene Panel Test Product Overview
  • Next Generation Sequencing Based Companion Diagnostic Assay
  • Next Generation Sequencing Based Companion Diagnostic Assay Product Overview
  • NGS Analysis Software
  • NGS Analysis Software Product Overview
  • Non-Invasive Prenatal Test – Down’s Syndrome
  • Non-Invasive Prenatal Test – Down’s Syndrome Product Overview
  • OGT SLE Test
  • OGT SLE Test Product Overview
  • OncoBEAM – Hepatocellular Carcinoma
  • OncoBEAM – Hepatocellular Carcinoma Product Overview
  • OncoBEAM – Pancreatic Cancer
  • OncoBEAM – Pancreatic Cancer Product Overview
  • Protein Biomarker Assay – Prostate Cancer
  • Protein Biomarker Assay – Prostate Cancer Product Overview
  • qUTI
  • qUTI Product Overview
  • Screening System – Cervical Cancer
  • Screening System – Cervical Cancer Product Overview
  • Sysmex XR-1000 Hematology Analyzer
  • Sysmex XR-1000 Hematology Analyzer Product Overview
  • Sysmex XR-2000 Hematology Analyzer
  • Sysmex XR-2000 Hematology Analyzer Product Overview
  • Sysmex XS-1000i AutoLoader Automated Hematology Analyzer – IG% Assay
  • Sysmex XS-1000i AutoLoader Automated Hematology Analyzer – IG% Assay Product Overview
  • Sysmex XS-1000i Automated Hematology Analyzer – IG% Assay
  • Sysmex XS-1000i Automated Hematology Analyzer – IG% Assay Product Overview
  • Sysmex Corp – Key Competitors
  • Sysmex Corp – Key Employees
  • Sysmex Corp – Key Employee Biographies
  • Sysmex Corp – Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
  • Recent Developments
  • Appendix

For more information about this company profile visit https://www.researchandmarkets.com/r/mnnyae

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.12235
$0.12235$0.12235
-0.91%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Shiba Inu Supply Shrinks as 167,991,300,000 SHIB Exit Exchanges

Shiba Inu Supply Shrinks as 167,991,300,000 SHIB Exit Exchanges

The post Shiba Inu Supply Shrinks as 167,991,300,000 SHIB Exit Exchanges appeared on BitcoinEthereumNews.com. -167,991,300,000 SHIB in exchange netflow Shiba Inu
Share
BitcoinEthereumNews2026/01/01 04:42
Kan de Solana koers naar $129 door grote SOL ETF instroom en hoge netwerkinkomsten?

Kan de Solana koers naar $129 door grote SOL ETF instroom en hoge netwerkinkomsten?

Solana sluit 2025 af met meer dan $1,5 miljard aan netwerkinkomsten. Daarmee laat het netwerk Ethereum en Hyperliquid samen achter zich. Deze cijfers van Blockworks
Share
Coinstats2026/01/01 03:16
Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

The post Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be appeared on BitcoinEthereumNews.com. Jordan Love and the Green Bay Packers are off to a 2-0 start. Getty Images The Green Bay Packers are, once again, one of the NFL’s better teams. The Cleveland Browns are, once again, one of the league’s doormats. It’s why unbeaten Green Bay (2-0) is a 8-point favorite at winless Cleveland (0-2) Sunday according to betmgm.com. The money line is also Green Bay -500. Most expect this to be a Packers’ rout, and it very well could be. But Green Bay knows taking anyone in this league for granted can prove costly. “I think if you look at their roster, the paper, who they have on that team, what they can do, they got a lot of talent and things can turn around quickly for them,” Packers safety Xavier McKinney said. “We just got to kind of keep that in mind and know we not just walking into something and they just going to lay down. That’s not what they going to do.” The Browns certainly haven’t laid down on defense. Far from. Cleveland is allowing an NFL-best 191.5 yards per game. The Browns gave up 141 yards to Cincinnati in Week 1, including just seven in the second half, but still lost, 17-16. Cleveland has given up an NFL-best 45.5 rushing yards per game and just 2.1 rushing yards per attempt. “The biggest thing is our defensive line is much, much improved over last year and I think we’ve got back to our personality,” defensive coordinator Jim Schwartz said recently. “When we play our best, our D-line leads us there as our engine.” The Browns rank third in the league in passing defense, allowing just 146.0 yards per game. Cleveland has also gone 30 straight games without allowing a 300-yard passer, the longest active streak in the NFL.…
Share
BitcoinEthereumNews2025/09/18 00:41